The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer.
about
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerRadioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology.Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer.Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.I-131 remnant ablation after thyroidectomy induced hepatotoxicity in a case of thyroid cancer.The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.Factors that influence radioactive iodine use for thyroid cancer.The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer.Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.Birth rates after radioactive iodine treatment for differentiated thyroid cancer.Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer.Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.(131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer.Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.Impact of the Amount of Liquid Intake on the Dose Rate of Patients Treated with Radioiodine.Sodium iodide symporter in the fight against thyroid cancer.The comparison of (131)I whole-body scans on the third and tenth day after (131)I therapy in patients with well-differentiated thyroid cancer: preliminary report.Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer.Blood cells in thyroid cancer patients: a possible influence of apoptosis.Radioactive iodine treatment for node negative papillary thyroid cancer with capsular invasion only: Results of a large retrospective study.Development and Evaluation of a Korean Version of a Thyroid-Specific Quality-of-Life Questionnaire Scale in Thyroid Cancer Patients.Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma
P2860
Q30367068-B09C8081-9E08-4EB5-814E-5CB0FA5D3982Q34318846-F4768F80-9202-4543-B874-2A367E72DAC9Q34918474-EB229029-2C2D-4448-B29A-10815EAAE50DQ35163702-614078F8-ABF3-4E98-87E7-783626FAF766Q35623586-45BFBC00-6BA1-46B4-8788-F3C61B8B27F1Q36128415-C1B7B297-5C4E-4D03-8FD1-5929CC88EEA6Q36602928-57CD4640-E429-4BB7-A603-E69CD75F17B1Q36666417-CB8D339D-C3D9-4652-A49C-77711E9A5EC3Q38063414-9260442E-2FBE-42C0-8DB3-0FD4CB740C75Q38230884-C2D5073F-3BAD-431D-9034-A759F6C470F7Q38400904-0449EEAA-67CD-4531-8F38-7865B2C7CF48Q38537454-BB528FCA-FF11-41AC-AA6D-0B2353D44409Q38645033-8F883D75-5DCB-4F25-9CEA-C9DFBBE1E23FQ40161746-A7D295AF-DE0A-4B7B-8AFF-529CE6D11614Q40495830-DE632EBB-89C1-43DD-AE44-92BA6CC4719BQ41031855-E5AB486B-0FFE-41D3-B617-1C05FCCD12B9Q41767919-A59FE3B0-E0C9-4542-A1BA-4B77F44CB8BFQ47207716-35EA65EE-0C6A-4BAA-B963-E83122585F11Q49752300-CEFE0E8F-C817-49D3-A54D-D4FEFF8EC30FQ50879323-BC6F7850-6C0F-4AE9-BF30-8DF59FDB79C3Q51479311-47ACF634-B8F2-4914-B85A-ED02442F9E6DQ52877329-4658814D-69C5-4F9C-9FDB-876F9A3DD449Q53510914-35988641-7148-40DD-9F81-CBE1850CADA6Q54514969-2558AD24-D45D-41C5-915E-F1768F17EA33Q55357065-A60CBAAF-EBE5-4573-B26E-62231BEBA82DQ57820497-12F4962E-D856-4F98-A9B9-D49ADD486E99
P2860
The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The benefits and risks of I-13 ...... differentiated thyroid cancer.
@en
The benefits and risks of I-13 ...... differentiated thyroid cancer.
@nl
type
label
The benefits and risks of I-13 ...... differentiated thyroid cancer.
@en
The benefits and risks of I-13 ...... differentiated thyroid cancer.
@nl
prefLabel
The benefits and risks of I-13 ...... differentiated thyroid cancer.
@en
The benefits and risks of I-13 ...... differentiated thyroid cancer.
@nl
P356
P1433
P1476
The benefits and risks of I-13 ...... differentiated thyroid cancer.
@en
P2093
Douglas Van Nostrand
P304
P356
10.1089/THY.2009.1611
P577
2009-12-01T00:00:00Z